Enzyme Replacement Therapy Market size is estimated to cross USD 14 Billion by the end of 2033, growing at a CAGR of 7% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of enzyme replacement therapy was USD 10 Billion. The growth of the market can be attributed to rising prevalence of lysosomal storage diseases (LSDs) in the population owing to rising diseases and an unhealthy lifestyle. There were 766 LSD diagnoses in the Australian population during the 12-year period, January 2009 through December 2020, including 32 successful pregnancies.
Also, the growing population is expected to boost the market further over the forecast period. The growth in population is anticipated to lead a rise in the prevalence of rare diseases, which is also expected to fuel the demand for enzyme replacement therapy. The population of the world is projected to rise by 2 billion people during the next 30 years, from 7.7 billion people today to 9.7 billion in 2050, with a potential peak of approximately 11 billion people around the year 2100.
The worldwide incidence of lysosomal storage illnesses, including Gaucher, Fabry, Pompe, and MPS, is steadily rising. For instance, as per information released by the National Institute of Neurological Disorders and Stroke in August 2021, approximately one in 40,000 individuals in the United States had Pompe disease, which is predicted to be roughly 32,950 individuals. Furthermore, the National Fabry Foundation estimates that the entire Fabry patient number in the USA will be roughly 7,713 in May 2020. As a result of the significant number of patients experiencing rare lysosomal storage illnesses, there is a huge requirement for efficient treatments, including enzyme replacement therapy.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
7% |
|
Base Year Market Size (2022) |
USD 10 Billion |
|
Forecast Year Market Size (2033) |
USD 14 Billion |
|
Regional Scope |
|
Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase)
The global enzyme replacement therapy market is segmented and analyzed for demand and supply by-products into agalsidase beta, imiglucerase, velaglucerase alfa, and others, out of which, the agalsidase beta segment is anticipated to garner the largest revenue by the end of 2033, backed by increasing prevalence of chronic disease in the population across the world owing to consumption of unhealthy food items and an engaged damaging lifestyle. Between 2000 and 2030, it was predicted that the number of Americans with chronic diseases would increase by around 45 million, or roughly 36%. Furthermore, the agalsidase segment held the second-largest market share in 2023. The increased cost and growing adoption of this medication in the treatment of Fabry disease are the principal factors for this segment's substantial market share.
Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency [EPI])
The global enzyme replacement therapy market is segmented and evaluated for demand and availability by disease into Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis, and exocrine pancreatic insufficiency [EPI], out of which, the exocrine pancreatic insufficiency segment captures the largest share in 2023 owing to the increasing incidence of this ailment amongst the general population. Furthermore, the high pervasiveness of exocrine pancreatic insufficiency among individuals suffering from chronic pancreatitis and cystic fibrosis contributes to a rise in the disease's patient group. This, in turn, contributes to this segment's supremacy over the forecast period. According to a Cleveland Clinic organization report, nearly 9 out of 10 infants with cystic fibrosis develop EPI during the first year. The remainder is in danger of developing EPI as children or adults.
Our in-depth analysis of the global enzyme replacement therapy market includes the following segments:
|
By Product |
|
|
By Disease |
|
|
By End-User |
|
Asia Pacific Market Forecast
The Asia Pacific enzyme replacement therapy market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033, owing to the growing number of patient population suffering from rare disorders, rising disposable income, growth in the healthcare sector, and an increase in government support. According to the Economist Intelligence Unit, 258 million individuals in Asia and the Pacific region suffer from rare diseases.
Europe Market Forecast
On the other hand, in 2023, Europe held the second-largest share of the worldwide market. The increase can be credited primarily to supportive regulatory policies in a few European nations for different infrequent lysosomal ailments, including Gaucher disease, MPS, and others. As per F1000 Research Ltd., the Polish National Health Fund, for instance, implemented a national drug program in 2019, with the first remuneration in ERT for Fabry disease. Furthermore, rapid advancements in medical infrastructure and a growing preference for therapeutic approaches for rare diseases drive market expansion in this region.
Teijin Limited announced the immediate availability of Revcovi 2.4 mg for intramuscular injection [Elapegademase (Genetic Recombination)]. With Revcovi 2.4 mg, Japan's first medication for Adenosine Deaminase (ADA) Deficiency, individuals with ADA Deficiency are expected to have improved ADA activity and immune system.
Clinigen Limited, a global pharmaceutical Products, and Services company, announced that Clinigen K.K., a fully owned subsidiary of Clinigen located in Tokyo, has gained manufacturing and marketing authorization for Hunterase (Idursulfase-beta) ICV 15mg as part of its strategic relationship with GC Pharma. The clearance of Hunterase ICV in Japan marks its first appearance in any nation globally.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?